Navigation Links
Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Date:8/10/2008

MIAMI, Aug. 11 /PRNewswire/ -- Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers, announced today that John W. Kilgour has been named Executive Vice President of Sales and Marketing. John is a healthcare professional with thirty-five years of business and management experience in both pharmaceutical and medical/surgical supply chain distribution.

Recently retired from Cardinal Health, John held positions of increasing responsibility for more than 35 years and most recently served as Vice President of Sales in Cardinal's Pharmaceutical Supply Chain Program. Primary responsibilities included sales to Integrated Delivery Networks (IDNs) and particular emphasis on resource leadership, coaching and developing Cardinal's related sales groups. Other key positions within Cardinal Health included sales management to national and regional Group Purchasing Organizations (GPOs) as well as managing pharmaceutical and medical supply sales and marketing initiatives for the acute care and managed care business segments.

Tom Burke, President and CEO of Novis Pharmaceuticals, said, "John will be a great mentor and teacher for our employees and an even better advocate for our customers. He has established longstanding, solid relationships and has a reputation of going the extra mile for clients, employees, and especially patients. His knowledge of the industry is second to none and we consider ourselves very fortunate to have him as part of the Novis team."

"I am excited to be here," added John Kilgour. "I am very impressed with Novis' core competencies and the really exceptional people who work here. This is a talented, enthusiastic and energetic group dedicated to exceeding customer expectations while meeting important patient need. Simply stated, the 'customer relationship' and 'dedication to patient need' is paramount in all that we do."

"This is a very challenging time in our industry," he continued. "Healthcare Providers are facing increasingly complex and more challenging disease states. Novis' product scope, its reliability for authenticity and pedigree tracking competencies are consistent with new important patient safety industry initiatives.

Novis Pharmaceuticals is committed to providing extraordinary service to their customers and patients and provides time-sensitive, life-saving medications nationwide, 24 hours a day - 7 days a week.

For more information about Novis Pharmaceuticals, please visit http://www.novispharma.com .

About NOVIS Pharmaceuticals

Novis Pharmaceuticals is a leading national distributor of some of the world's leading plasma-derived products such as albumin, immune globulin, hyperimmunes and anti-hemophilic Factors VII, VIII and IX. Hospitals, home infusion therapy companies and other healthcare providers use these biotherapeutics to treat trauma, autoimmune conditions, immune deficiencies, infectious diseases, bleeding disorders, and other life-threatening conditions.


'/>"/>
SOURCE Novis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
2. Novis Pharmaceuticals Hires Lisa Lopez
3. Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
4. Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link
5. Renovis Announces Management Changes
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
7. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
8. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
9. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
10. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
11. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: